View in EDS

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.

Saved in:
Bibliographic Details
Title: Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
Authors: IIIBurris, Howard A1,2, Flinn, Ian W1,2, Patel, Manish R1,3, Fenske, Timothy S4, Deng, Changchun5, Brander, Danielle M6, Gutierrez, Martin7, Essell, James H8, Kuhn, John G9, Miskin, Hari P10, Sportelli, Peter10, Weiss, Michael S10, Vakkalanka, Swaroop11, Savona, Michael R12, O'Connor, Owen A5 owenoconnor@columbia.edu, Burris, Howard A 3rd13, O'Connor, Owen A5
Source: Lancet Oncology. Apr2018, Vol. 19 Issue 4, p486-496. 11p.
Database: Academic Search Ultimate
Description
ISSN:14702045
DOI:10.1016/S1470-2045(18)30082-2